COMP <GO>
TXG vs RVTY // ENTERPRISE SCALE & MARKET CAP
10x Genomics Inc. (NASDAQ) VS. Revvity Inc. (NYSE) • 15-METRIC TALLY: TXG 5
— RVTY 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: RVTY
LAST: $81.55 (-2.47%) • MKT CAP: $10.63B
market-cap
$10.63B
LAST: $165.78 (+0.27%) • MKT CAP: $18.50B
market-cap
$18.50B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. RVTY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | RVTY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 3.10% | -8.80 | RVTY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 48.2x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 2.75% | -1.53 | RVTY | /fcf-yield <GO> |
| Operating Margin | -9.50% | 12.50% | -22.00 | RVTY | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 8.40% | -15.20 | RVTY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | 3.70% | +1.50 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.18% | -0.18 | RVTY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 3.37 | +21.65 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.0 | 64.5 | -9.50 | RVTY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.95 | +0.20 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 71.3x | -47.30 | TXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $10.63B | $18.50B | -$7.87B | RVTY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | RVTY REV | TXG GROSS % | RVTY GROSS % | TXG FCF | RVTY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $2.86B | 69.1% | — | $130.1M | $509.4M |
| FY 2024 | $610.8M | $2.76B | 67.9% | — | -$5.7M | $541.7M |
| FY 2023 | $618.7M | $2.75B | — | — | -$43.0M | -$32.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
RVTY // BETA 0.95